The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4611-4619

  Ma, Xiao Jun ^a   Hilsenbeck, Susan G ^a   Wang, Wilson ^a   Ding, Li ^a   Sgroi, Dennis C ^a   Bender, Richard A ^a   Osborne, C Kent ^a   Allred, D Craig ^a   Erlander, Mark G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DEHYDROGENASE; ESTROGEN RECEPTOR; FORMALDEHYDE; HOMEODOMAIN PROTEIN; INTERLEUKIN RECEPTOR; MESSENGER RNA; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN HOXB13; PROTEIN IL17BR; TAMOXIFEN; UNCLASSIFIED DRUG; HOXB13 PROTEIN, HUMAN; IL17RB PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED;

AGED; BREAST NEOPLASMS; CHOLINE DEHYDROGENASE; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, INTERLEUKIN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 33750598939     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6944     Document Type: Article

References (39)

1. Carlson RW, McCormick B: Update: NCCN Breast Cancer Clinical Practice Guidelines. J Natl Compr Cane Netw 3:S7-S11, 2005
2. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583, 2005
3. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
5. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
6. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458, 2001
7. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
8. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
9. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
10. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
11. Huang E, Cheng SH, Dressman H, et al: Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596, 2003
12. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor sUBClasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
13. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
14. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
15. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004
16. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005
17. Goetz M, Suman V, Ingle JN, et al: A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clinical Cancer Res 12:2080-2087, 2006
18. Martin MD, Hilsenbeck SG, Mohsin SK, et al: Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95:7-12, 2006
19. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
20. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004
21. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
22. Tanner M, Gancberg D, Di Leo A, et al: Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467-1472, 2000
23. Vandesompele J, De Prefer K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034, 2002
24. Fraley C, Raftery AE: MCLUST: Software for model-based cluster analysis. J Class 16:297-306, 1999
25. Therneau TM, Grambsch PM, Flemming TR: Martingale-based residuals for survival analysis. Biometrika 77:216-218, 1990
26. Pettitt AN, Bin Daud I: Investigating time dependence in Cox's proportional hazards model. Appl Stat 39:205-217, 1990
27. Faraggi D, Simon R: A simulation study of cross-validation for selecting an optimal outpoint in univariate survival analysis. Stat Med 15:2203-2213, 1996
28. R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2005
29. Yeung KY, Fraley C, Murua A, et al: Model-based clustering and data transformations for gene expression data. Bioinformatics 17:977-987, 2001
30. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004
31. Tong D, Schneeberger C, Czerwenka K, et al. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer. Clin Cancer Res 5:1497-1502, 1999
32. Jansen MP, Foekens JA, Klijn JG, et al: Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97:1851-1853, 2005
33. Reid JF, Lusa L, De Cecco L, et al: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97:927-930, 2005
34. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
35. Tian E, Sawyer JR, Largaespada DA, et al: Evi27 encodes a novel membrane protein with homology to the IL17 receptor. Oncogene 19:2098-2109, 2000
36. Chen H, Sukumar S: HOX genes: Emerging stars in cancer. Cancer Biol Ther 2:524-525, 2003
37. Svingen T, Tonissen KF: Altered HOX gene expression in human skin and breast cancer cells. Cancer Biol Ther 2:518-523, 2003
38. Maeda K, Hamada J, Takahashi Y, et al: Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer 114:436-441, 2005
39. Yamashita T, Tazawa S, Yawei Z, et al: Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol 28:931-938, 2006